| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5690960 | COVIS | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
| US5900424 | COVIS | Omeprazole magnesium salt form |
May, 2016
(8 years ago) | |
| US6428810 | COVIS | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) | |
Prilosec is owned by Covis.
Prilosec contains Omeprazole Magnesium.
Prilosec has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Prilosec are:
- US5690960
- US5900424
- US6428810
Prilosec was authorised for market use on 20 March, 2008.
Prilosec is available in for suspension, delayed release;oral dosage forms.
Prilosec can be used as pediatric use ages 1-2 years, gerd and erosive esophagitis.
The generics of Prilosec are possible to be released after 03 November, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Drugs and Companies using OMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 20 March, 2008
Treatment: Pediatric use ages 1-2 years, gerd and erosive esophagitis
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL
PRILOSEC family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6147103 | ASTRAZENECA | Omeprazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6191148 | ASTRAZENECA | Omerazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6166213 | ASTRAZENECA | Omeprazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6150380 | ASTRAZENECA | Crystalline form of omeprazole |
Nov, 2018
(5 years ago) | |
|
US6191148 (Pediatric) | ASTRAZENECA | Omerazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6147103 (Pediatric) | ASTRAZENECA | Omeprazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6166213 (Pediatric) | ASTRAZENECA | Omeprazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6150380 (Pediatric) | ASTRAZENECA | Crystalline form of omeprazole |
May, 2019
(4 years ago) | |
Prilosec is owned by Astrazeneca.
Prilosec contains Omeprazole.
Prilosec has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Prilosec are:
- US6147103
- US6191148
- US6166213
- US6150380
- US6191148*PED
- US6147103*PED
- US6166213*PED
- US6150380*PED
Prilosec was authorised for market use on 05 October, 1995.
Prilosec is available in capsule, delayed rel pellets;oral dosage forms.
The generics of Prilosec are possible to be released after 10 May, 2019.
Drugs and Companies using OMEPRAZOLE ingredient
Market Authorisation Date: 05 October, 1995
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL
PRILOSEC family patents